Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Samuel G.W. Ow, Diana Lim, Tuan Zea Tan, Junxian Zhu et al.
Citations
8 citations
Journal
Clinical Cancer Research
Topics
Ovarian cancer diagnosis and treatment
Field-Weighted Citation Impact (FWCI)
13.58
article
Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Samuel G.W. Ow, Diana Lim, Tuan Zea Tan, Junxian Zhu, Michael Leonard Friedlander, Haoyang Sun, Natalie Y.L. Ngoi, Hee Seung Kim, Jae‐Weon Kim, Kidong Kim, David S.P. Tan, Wen Yee Chay, Chel Hun Choi, Geraldine Goss, Siew Eng Lim, Valerie Heong, Bee Choo Tai, Jeffrey C. Goh, Yi Wan Lim
article en
8 citations
Abstract
No abstract available for this paper.
Publication Tag
Clinical Cancer ResearchVol. 31(18)
Institutions
Box Hill Hospital (AU), Seoul National University (KR), National University of Singapore (SG), Royal Brisbane and Women's Hospital (AU), Samsung Medical Center (KR), Tan Tock Seng Hospital (SG), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), UNSW Sydney (AU), National University Cancer Institute, Singapore (SG), Prince of Wales Hospital (AU), National Cancer Centre Singapore (SG), National University Hospital (SG), National University Health System (SG), Bristol-Myers Squibb (South Korea) (KR)
Funders
AstraZeneca, Medical Research Council, National Medical Research Council